Valencia restarts Gardasil shots; Generics maker plans new Malta plant

> The Spanish region of Valencia has resumed cervical cancer vaccinations using Merck's Gardasil, a health authority spokeswoman told Reuters, though one batch is still suspended and under investigation. Report

> Generics maker Pharmacare Premium plans to invest €10 million in a new Malta plant that will employ 60 people when it begins operating next year. Report

> Swedish pharma Orexo AB said it has inked a distribution agreement with Israel's Neopharm, giving the latter exclusive rights to sell Orexo's cancer pain treatment Abstral in Israel. Report

> Roche has had its membership to the Association of the British Pharmaceutical Industry reinstated after serving a seven month suspension for breaching its code of convention. Report

> Warren Buffett's Berkshire Hathaway reduced its stake in Johnson & Johnson by 54 percent to 28.6 million shares in the three months ended Dec. Report

> NeuroSearch is getting a capital injection of $22 million after signing a new R&D pact with Eli Lilly. Report

> A group of investors has stepped in to buy $42 million worth of shares in Affymax. The private placement gives the developer added funds for the late-stage development of Hematide. Report

> Breaking a therapeutic drought that has stretched over more than four decades, Takeda says it has won the FDA's approval of its new gout drug Uloric. Report

> Canada's Bradmer Pharmaceuticals says the CRO it hired for a late-stage brain cancer study "has indicated that it is unable to meet the targets for site initiation and enrollment of sufficient patients in a timely manner." Report

> Bioengineering experts are urging the adoption of open technology platforms that will hasten the creation of genetic materials and new drugs. Report

> If you dig deep into the Star-Ledger's article on Merck's ambitious plans to jump into the biosimilar business, you'll find that it will depend a lot on the success of the development technology advanced by Glycofi, a little company that it snapped up in 2006. Report

And Finally... A government report says the rate of dangerous staph infections has dropped dramatically in hospital intensive-care units, a rare encouraging sign about a hard-to-treat "superbug." Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.